Annals of Diagnostic Pathology
Volume 12, Issue 4 , Pages 275-282 , August 2008

Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis

  • Martha Lilia Tena-Suck, MD

      Affiliations

    • Departamento de Patología Experimental, Instituto Nacional de Neurología y Neurocirugía, Mexico City, cp. 14269 Mexico
    • Corresponding Author InformationCorresponding author. Departamento de Neuropatología, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez,” Av Insurgentes Sur 3877 Col. La Fama, Tlalpan CP 14269, Mexico, DF, Mexico. Tel.: +525 56063822x2008.
    • ,
  • Alma Ortiz-Plata, PhD

      Affiliations

    • Departamento de Patología Experimental, Instituto Nacional de Neurología y Neurocirugía, Mexico City, cp. 14269 Mexico
    • ,
  • Horacio Astudillo de la Vega, PhD

      Affiliations

    • Laboratorio de Oncología Molecular, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncologia, Centro Medico Nacional Siglo XXI, IMSS, Mexico City, cp. 06720 Mexico

References 

  1. Yu R, Melmed S. Oncogene activation in pituitary tumors. Brain Pathol. 2001;111:328–341
  2. Bai F, Pei XH, Pandolfi PP, Xiong Y. p18 Ink4c and PTEN constrain a positive regulatory loop between cell growth and cell cycle control. Mol Cell Biol. 2006;26:4564–4576
  3. Faglia G, Spada A. Genesis of pituitary adenomas: state of the art. J Neurooncol. 2001;54:95–110
  4. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–2927
  5. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999;96:4240–4245
  6. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–1657
  7. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer. 2005;12:423–433
  8. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res. 2006;4:130–137
  9. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1999;l13:156–166
  10. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000;157:1097–1103
  11. Tachibana M, Shibakita M, Ohno S, Kinugasa S, Yoshimura H, Ueda S, et al. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer. 2002;94:1955–1960
  12. Tao J, Xiong J, Li T, Yang Z, Li X, Li K, et al. Correlation between protein expression of PTEN in human pancreatic cancer and the proliferation, infiltration, metastasis and prognosis. J Huazhong Univ Sci Technolog Med Sci. 2006;26:444–447
  13. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J Biol Chem. 1998;273:13375–13378
  14. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994;7:480–484
  15. Liu W, Asa SL, Ezzat S. Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. Brain Pathol. 2002;12:412–419
  16. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000;156:1693–1700
  17. Ferreira JE, de Mello PA, de Magalhaes AV, Botelho CH, Naves LA, Nosé V, et al. Non-functioning pituitary adenomas: clinical features and immunohistochemistry. Arq Neuropsiquiatr. 2005;63:1070–1078
  18. Pawlikowski M, Gruszka A, Kurnatowska I, Winczyk K, Kunert-Radek J, Radek A. Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem Cytobiol. 2006;44:37–41
  19. Ortiz-Plata A, Tena Suck ML, López-Gómez M, Heras A, Sánchez García A. Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics. J Neurooncol. 2007;84:59–66
  20. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59:341–353

PII: S1092-9134(08)00020-8

doi: 10.1016/j.anndiagpath.2008.02.001

Annals of Diagnostic Pathology
Volume 12, Issue 4 , Pages 275-282 , August 2008

Article Tools

* Image Usage & Resolution